Drug Profile
Research programme: small molecule therapeutics - Nuredis
Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator National Yang-Ming University; Stanford University
- Developer Nuredis
- Class Small molecules
- Mechanism of Action DNA modulators; Transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Huntington's disease
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for research development in Huntington's-disease in Taiwan
- 28 Aug 2021 No recent reports of development identified for research development in Huntington's-disease in USA
- 11 Jul 2017 Early research in Huntington's disease in USA, Taiwan (unspecified route)